TRASTUZUMAB-DKST
Manufacturer: Biocon Biologics Inc.
Score: 144.0
OGIVRI (TRASTUZUMAB-DKST) is a humanized IgG1 kappa monoclonal antibody used for the treatment of HER2-overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. The drug has been shown to inhibit the proliferation of human tumor cells that overexpress HER2 and is a mediator of antibody-dependent cellular cytotoxicity. Important safety information includes the risk of cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity. The recommended dose is 4 mg/kg as an initial dose, followed by 2 mg/kg weekly for 12 weeks, and then 6 mg/kg every 3 weeks for a total of 52 weeks of therapy in adjuvant breast cancer. Special population considerations include use during pregnancy, pediatric use, and geriatric use.
Cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity
Dose adjustments may be necessary for patients with cardiomyopathy or infusion reactions
4 mg/kg initial dose, followed by 2 mg/kg weekly for 12 weeks, and then 6 mg/kg every 3 weeks for a total of 52 weeks of therapy
4 mg/kg initial dose, followed by 2 mg/kg weekly until disease progression
8 mg/kg initial dose, followed by 6 mg/kg every 3 weeks until disease progression